Literature DB >> 20381650

Increase in vertebral body size in postmenopausal women with osteoporosis.

K Briot1, S Kolta, J Fechtenbaum, R Said-Nahal, C L Benhamou, C Roux.   

Abstract

Bone geometry plays a prominent role in bone strength. Cross-sectional studies have shown that advancing age is associated with increasing diameter of long bones, related to both periostal apposition and endosteal resorption. However, there are few data provided by prospective studies, especially concerning the changes in vertebral body dimensions. The objective of this prospective study was to measure the changes occurring in the vertebral body size of women with postmenopausal osteoporosis. Three-year data from placebo groups of the SOTI and TROPOS trials, performed in women with postmenopausal osteoporosis, were used for this study. In these trials, patients underwent lateral radiographs of the thoracic and lumbar spine at baseline and annually over 3 years, according to standardized procedures. Six-point digitization method was used: the four corner points of the vertebral body from T4 to L4 are marked, as well as an additional point in the middle of the upper and lower endplates. From these 6 points, the vertebral body perimeter, area and depth were measured at baseline and at 3 years. The analysis excluded all vertebrae with prevalent or incident fracture. A total of 2017 postmenopausal women (mean age 73.4+/-6.1 years) with a mean lumbar spine T score of -3.1+/-1.5, and a mean femoral neck T score of -3.0+/-0.7 are included in the analysis. Vertebral body dimensions increased over 3 years, by 2.1+/-5.5% (mean depth+/-SD), by 1.7+/-8.3% (mean area+/-SD) and by 1.5+/-4.9% (mean perimeter+/-SD) at the thoracic level (T4 to T12). At the lumbar level (L1 to L4), these dimensions increased as well: 1.4+/-3.6% (mean depth+/-SD), 1.4+/-5.7% (mean area+/-SD), 0.7+/-2.9% (mean perimeter+/-SD). A significant increase in vertebral body size was observed for each vertebral level from T5 to L4 for each of these parameters (p<0.01). These prospective results demonstrate that vertebral body dimensions increase over 3 years in women with postmenopausal osteoporosis. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20381650     DOI: 10.1016/j.bone.2010.03.020

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  6 in total

1.  Morphological studies of cartilage endplates in subaxial cervical region.

Authors:  Songchuan Zhao; Dingjun Hao; Yonghong Jiang; Dageng Huang; Chaoyuan Ge; Hang Feng
Journal:  Eur Spine J       Date:  2015-11-26       Impact factor: 3.134

2.  The ratio of anterior and posterior vertebral heights reinforces the utility of DXA in assessment of vertebrae strength.

Authors:  Grzegorz Tatoń; Eugeniusz Rokita; Mariusz Korkosz; Andrzej Wróbel
Journal:  Calcif Tissue Int       Date:  2014-05-23       Impact factor: 4.333

3.  Hypothalamic leptin gene therapy reduces body weight without accelerating age-related bone loss.

Authors:  Russell T Turner; Michael Dube; Adam J Branscum; Carmen P Wong; Dawn A Olson; Xiaoying Zhong; Mercedes F Kweh; Iske V Larkin; Thomas J Wronski; Clifford J Rosen; Satya P Kalra; Urszula T Iwaniec
Journal:  J Endocrinol       Date:  2015-10-20       Impact factor: 4.286

4.  Application of geometrical measurements in the assessment of vertebral strength.

Authors:  Grzegorz Tatoń; Eugeniusz Rokita; Andrzej Wróbel
Journal:  Pol J Radiol       Date:  2013-04

5.  Analysis of percutaneous kyphoplasty under different types of anesthesia for the treatment of multiple osteoporotic vertebral fractures.

Authors:  Shuai Zhang; Shuang Xu; Jin Yang; Song Wang; Qing Wang
Journal:  BMC Musculoskelet Disord       Date:  2020-11-12       Impact factor: 2.362

6.  Combining areal DXA bone mineral density and vertebrae postero-anterior width improves the prediction of vertebral strength.

Authors:  Grzegorz Tatoń; Eugeniusz Rokita; Andrzej Wróbel; Mariusz Korkosz
Journal:  Skeletal Radiol       Date:  2013-10-01       Impact factor: 2.199

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.